Waddill William D. 4

What Happened

• William D. Waddill, a director of Protagonist Therapeutics (PTGX), exercised 9,000 stock options and immediately sold 9,000 shares on May 29, 2026.
• Exercise: 9,000 shares exercised at $11.80 per share for a total exercise cost of $106,200 (transaction code M).
• Sale: 9,000 shares sold in an open market transaction at $99.64 per share, generating $896,760 (transaction code S).
• The filing also shows a derivative disposition of 9,000 at $0 (code M), which reflects cancellation/disposition of the option after exercise.
• Net proceeds before fees and taxes are approximately $790,560 (sale proceeds minus exercise cost).

Key Details

• Transaction date: May 29, 2026.
• Prices: exercised at $11.80; sold at $99.64.
• Shares owned following the transactions: not specified in the provided filing.
• Footnotes: Transactions were executed under a 10b5-1 trading plan adopted by Waddill on February 27, 2026 (F1). The stock options exercised were fully vested (F2).
• Filing timeliness: No late-filing indication provided in the supplied data.

Context

• This was an exercise of vested options followed by an immediate open-market sale (a common cashless-style outcome where exercised shares are sold soon after issuance).
• The presence of a 10b5-1 plan indicates the sale was pre-planned according to a trading arrangement adopted before the trade date; this is routine and intended to avoid accusations of opportunistic trading based on material nonpublic information.
• The transactions are factual disclosures and do not by themselves indicate the insider’s future view of the company.